<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1154"/><api:result><api:object category="publication" id="1154" last-affected-when="2024-03-14T05:46:10.937+00:00" last-modified-when="2024-03-14T05:46:10.937+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1154" created-when="2010-05-17T13:47:32.517+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-01-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2349532" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1023/A:1008383707159" last-modified-when="2022-09-11T03:11:09.65+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Howell</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Eggleton</api:last-name><api:initials>SPH</api:initials><api:first-names>SPH</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>P</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Maling</api:last-name><api:initials>SJ</api:initials><api:first-names>SJ</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Miles</api:last-name><api:initials>DW</api:initials><api:first-names>DW</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008383707159</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008383707159"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008383707159"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>541</api:begin-page><api:end-page>546</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1023/a:1008383707159</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>20</api:day><api:month>2</api:month><api:year>2020</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>A Phase II study of docetaxel in patients with liver metastases from breast cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="3522584" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0343496937" last-modified-when="2024-02-20T17:43:29.477+00:00"><api:citation-count>14</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Background: Previous phase II studies of docetaxel have indicated that hepatic metastases from breast cancer respond well to first-line treatment with docetaxel. The objective of this prospective, open label phase II study therefore was specifically to evaluate the activity and safety of docetaxel in this indication. Patients and methods: The study recruited 47 women (mean age 50 years, range 33-66 years) with hepatic metastases from breast cancer who fulfilled the eligibility criteria. After premedication with steroids, patients received a one-hour intravenous infusion of docetaxel 100 mg/m2 at three-weekly intervals for up to eight cycles. Response to treatment during medication was assessed after three, six and where appropriate, eight cycles and every three month follow-up thereafter, until disease progression or death. Results: The best overall response rate (ORR) for evaluable patients was 64.3% (95% CI: 48.0%-78.5%). In terms of the primary efficacy parameters, the ORR at the sixth cycle of treatment was 62% (95% CI: 45%-80%) with 17% complete responses. The median duration of response was 139 days (95% CI: 111-216 days) and the median survival duration calculated on an intent-to- treat basis was 335 days (227-568 days, 95% CI). One (2%) toxic death was reported. Conclusions: Docetaxel is a highly effective cytotoxic agent in the treatment of patients with liver metastases from breast cancer.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7403206142</api:identifier></api:identifiers></api:person><api:person><api:last-name>Howell</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Christie NHS Foundation Trust</api:line><api:line type="city">Manchester</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7102028981</api:identifier></api:identifiers></api:person><api:person><api:last-name>Eggleton</api:last-name><api:initials>SPH</api:initials><api:first-names>SPH</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>P</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="FR"><api:line type="organisation">Sanofi S.A.</api:line><api:line type="city">Gentilly</api:line><api:line type="country">France</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57215675289</api:identifier></api:identifiers></api:person><api:person><api:last-name>Maling</api:last-name><api:initials>SJ</api:initials><api:first-names>SJ</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Aventis Pharma Ltd.</api:line><api:line type="city">West Malling</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57159886300</api:identifier></api:identifiers></api:person><api:person><api:last-name>Miles</api:last-name><api:initials>DW</api:initials><api:first-names>DW</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Guy's and St Thomas' NHS Foundation Trust</api:line><api:line type="city">London</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7201525174</api:identifier></api:identifiers></api:person><api:person><api:last-name>Atkins</api:last-name><api:initials>MJ</api:initials><api:first-names>MJ</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Aventis Pharma Ltd.</api:line><api:line type="city">West Malling</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57197464342</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/A:1008383707159</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/A:1008383707159"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/A:1008383707159"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10907946</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>541</api:begin-page><api:end-page>546</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase II study of docetaxel in patients with liver metastases from breast cancer</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="1154" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10907946" last-modified-when="2020-04-29T00:34:33.37+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND: Previous phase II studies of docetaxel have indicated that hepatic metastases from breast cancer respond well to first-line treatment with docetaxel. The objective of this prospective, open label phase II study therefore was specifically to evaluate the activity and safety of docetaxel in this indication. PATIENTS AND METHODS: The study recruited 47 women (mean age 50 years, range 33-66 years) with hepatic metastases from breast cancer who fulfilled the eligibility criteria. After premedication with steroids, patients received a one-hour intravenous infusion of docetaxel 100 mg/m2 at three-weekly intervals for up to eight cycles. Response to treatment during medication was assessed after three, six and where appropriate, eight cycles and every three month follow-up thereafter, until disease progression or death. RESULTS: The best overall response rate (ORR) for evaluable patients was 64.3% (95% CI: 48.0-78.5%). In terms of the primary efficacy parameters, the ORR at the sixth cycle of treatment was 62% (95% CI: 45%-80%) with 17% complete responses. The median duration of response was 139 days (95% CI: 111-216 days) and the median survival duration calculated on an intent-to-treat basis was 335 days (227-568 days, 95% CI). One (2%) toxic death was reported. CONCLUSIONS: Docetaxel is a highly effective cytotoxic agent in the treatment of patients with liver metastases from breast cancer.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Weston Park Hospital NHS Trust, Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Howell</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Eggleton</api:last-name><api:initials>SP</api:initials><api:first-names>SP</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Maling</api:last-name><api:initials>SJ</api:initials><api:first-names>SJ</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Miles</api:last-name><api:initials>DW</api:initials><api:first-names>DW</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10907946</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008383707159</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008383707159"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008383707159"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Ann Oncol</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Disease Progression</api:keyword><api:keyword scheme="mesh">Docetaxel</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Paclitaxel</api:keyword><api:keyword scheme="mesh">Taxoids</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>541</api:begin-page><api:end-page>546</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0923-7534(19)55057-8</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>28</api:day><api:month>12</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Clinical Trial, Phase II</api:item><api:item>Journal Article</api:item><api:item>Multicenter Study</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="882259" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10907946" last-modified-when="2021-01-19T17:57:18.67+00:00"><api:citation-count>11</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Background&lt;/h4&gt;Previous phase II studies of docetaxel have indicated that hepatic metastases from breast cancer respond well to first-line treatment with docetaxel. The objective of this prospective, open label phase II study therefore was specifically to evaluate the activity and safety of docetaxel in this indication.&lt;h4&gt;Patients and methods&lt;/h4&gt;The study recruited 47 women (mean age 50 years, range 33-66 years) with hepatic metastases from breast cancer who fulfilled the eligibility criteria. After premedication with steroids, patients received a one-hour intravenous infusion of docetaxel 100 mg/m2 at three-weekly intervals for up to eight cycles. Response to treatment during medication was assessed after three, six and where appropriate, eight cycles and every three month follow-up thereafter, until disease progression or death.&lt;h4&gt;Results&lt;/h4&gt;The best overall response rate (ORR) for evaluable patients was 64.3% (95% CI: 48.0-78.5%). In terms of the primary efficacy parameters, the ORR at the sixth cycle of treatment was 62% (95% CI: 45%-80%) with 17% complete responses. The median duration of response was 139 days (95% CI: 111-216 days) and the median survival duration calculated on an intent-to-treat basis was 335 days (227-568 days, 95% CI). One (2%) toxic death was reported.&lt;h4&gt;Conclusions&lt;/h4&gt;Docetaxel is a highly effective cytotoxic agent in the treatment of patients with liver metastases from breast cancer.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Weston Park Hospital NHS Trust, Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Howell</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-6233-719X</api:identifier></api:identifiers></api:person><api:person><api:last-name>Eggleton</api:last-name><api:initials>SP</api:initials><api:first-names>SP</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Maling</api:last-name><api:initials>SJ</api:initials><api:first-names>SJ</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Miles</api:last-name><api:initials>DW</api:initials><api:first-names>DW</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008383707159</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008383707159"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008383707159"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1569-8041</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10907946</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of oncology : official journal of the European Society for Medical Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Disease Progression</api:keyword><api:keyword scheme="mesh">Taxoids</api:keyword><api:keyword scheme="mesh">Paclitaxel</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Docetaxel</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>541</api:begin-page><api:end-page>546</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>25</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial, Phase II</api:item><api:item>Clinical Trial</api:item><api:item>Multicenter Study</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record><api:record format="native" id="2927090" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1056303635" last-modified-when="2024-03-14T05:46:11.033+00:00"><api:citation-count>11</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>3</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1991" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1991"/></api:links><api:last-name>Coleman</api:last-name><api:initials>RE</api:initials><api:first-names>RE</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>E</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014331105607.96</api:identifier></api:identifiers></api:person><api:person><api:last-name>Howell</api:last-name><api:initials>A</api:initials><api:first-names>A</api:first-names><api:separate-first-names><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Christie NHS Foundation Trust</api:line><api:line type="city">Manchester</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01005610111.35</api:identifier></api:identifiers></api:person><api:person><api:last-name>Eggleton</api:last-name><api:initials>SPH</api:initials><api:first-names>SPH</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>P</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Rhone-Poulenc Rorer Ltd, West Mailing, Kent, UK</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01214077000.48</api:identifier></api:identifiers></api:person><api:person><api:last-name>Maling</api:last-name><api:initials>SJ</api:initials><api:first-names>SJ</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Aventis Pharma Ltd, West Mailing, Kent, UK</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Miles</api:last-name><api:initials>DW</api:initials><api:first-names>DW</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">National Health Service England</api:line><api:line type="city">London</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01043410075.28</api:identifier></api:identifiers></api:person><api:person><api:last-name>group</api:last-name><api:initials>OBOAUS</api:initials><api:first-names>on behalf of A UK study</api:first-names><api:separate-first-names><api:first-name>on</api:first-name><api:first-name>behalf</api:first-name><api:first-name>of</api:first-name><api:first-name>A</api:first-name><api:first-name>UK</api:first-name><api:first-name>study</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1023/a:1008383707159</api:text><api:links><api:link type="doi" href="http://doi.org/10.1023/a:1008383707159"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1023/a:1008383707159"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10907946</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>1.44</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0923-7534</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>5</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Annals of Oncology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Liver Disease</api:keyword><api:keyword scheme="rcdc">Digestive Diseases</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Breast Cancer</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Adult</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Breast Neoplasms</api:keyword><api:keyword scheme="mesh">Disease Progression</api:keyword><api:keyword scheme="mesh">Docetaxel</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Liver Neoplasms</api:keyword><api:keyword scheme="mesh">Middle Aged</api:keyword><api:keyword scheme="mesh">Paclitaxel</api:keyword><api:keyword scheme="mesh">Taxoids</api:keyword><api:keyword scheme="mesh">Treatment Outcome</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>541</api:begin-page><api:end-page>546</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>5</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.37</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>A Phase II study of docetaxel in patients with liver metastases from breast cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>11</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Disease Progression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Docetaxel</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Paclitaxel</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Taxoids</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Disease Progression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Taxoids</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Paclitaxel</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Treatment Outcome</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Docetaxel</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Liver Disease</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Digestive Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Breast Cancer</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Adult</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Breast Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Disease Progression</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Docetaxel</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Liver Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Middle Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Paclitaxel</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Taxoids</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Treatment Outcome</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3202 Clinical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0923-7534" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973567" title="Annals of Oncology"><api:records><api:record source-name="summary"><api:title>Annals of Oncology</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1154/relationships"/></api:object></api:result></api:response>